Long-term follow-up result of antithyroid drug treatment of Graves’ hyperthyroidism in a large cohort
Authors' conclusion
ATD treatment is an acceptable option for the initial treatment of Graves' hyperthyroidism as well as for recurrent disease. The optimal treatment period for ATD treatment needs to be determined using the individual risk factors of recurrence.
Study context
- Population
- Patients newly diagnosed with Graves' hyperthyroidism with sufficient follow-up data; median age 44.5 years, 69% female
- Participants
- 1,829 patients
- Outcome
- Efficacy of antithyroid drugs (ATDs) (remission) and risk factors for recurrence-free survival
Main finding
As reported in the abstract
First remission rate after ATD · median 72.7 months of follow-up
ATD
55.6%
- Had chance to withdraw ATD
- 1235
- Median ATD duration before withdrawal (IQR 17.0-35.5)
- 23 months
Observational data: associations, not effects.
Further findings
Remission after second ATD course following first recurrence
- Underwent second ATD course
- 95%
- Median second-course duration (IQR 14.8-31.7)
- 21.1 months
- Remission rate
- 54.1%
Definitive treatment and ongoing ATD · median 67 months of follow-up
- Surgery
- 7.7%
- RAI
- 10.5%
- Still on ATD (recurrent disease or prolonged low-dose maintenance)
- ≈30%
Original publication
Long-term follow-up result of antithyroid drug treatment of Graves’ hyperthyroidism in a large cohort. Eur Thyroid J. Published 17 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →